About
Dr. Nadja Mannowetz is the Chief Scientific Officer of YourChoice Therapeutics, who is working on a novel inhibitor of the male contraceptive target Retinoic Acid Receptor Alpha. With a background in sperm biology, Nadja co-founded YourChoice Therapeutics in 2018 with the goal of developing non-hormonal contraceptive products for men and women.

Our Grant
MCI is supporting YourChoice’s work in developing a reversible male contraceptive that prevents the production of new sperm. MCI’s grant will facilitate work that progresses a drug candidate towards first-in-human studies and eventual FDA approval.